Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021
<p><strong>Objective:</strong> To understand community seroprevalence of SARS-CoV-2 in children and adolescents. This is vital to understanding the susceptibility of this cohort to COVID-19 and to inform public health policy for disease control such as immunisation.</p&...
| প্রধান লেখক: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| বিন্যাস: | Journal article |
| ভাষা: | English |
| প্রকাশিত: |
BMJ Publishing Group
2022
|
| _version_ | 1826313151190138880 |
|---|---|
| author | Ratcliffe, H Tiley, KS Andrews, N Amirthalingam, G Vichos, I Morey, E Douglas, NL Marinou, S Plested, E Aley, P Galiza, EP Faust, SN Hughes, S Murray, CS Roderick, M Shackley, F Oddie, SJ Lees, T Turner, DPJ Raman, M Owens, S Turner, P Cockerill, H Lopez Bernal, J Linley, E Borrow, R Brown, K Ramsay, ME Voysey, M Snape, MD |
| author_facet | Ratcliffe, H Tiley, KS Andrews, N Amirthalingam, G Vichos, I Morey, E Douglas, NL Marinou, S Plested, E Aley, P Galiza, EP Faust, SN Hughes, S Murray, CS Roderick, M Shackley, F Oddie, SJ Lees, T Turner, DPJ Raman, M Owens, S Turner, P Cockerill, H Lopez Bernal, J Linley, E Borrow, R Brown, K Ramsay, ME Voysey, M Snape, MD |
| author_sort | Ratcliffe, H |
| collection | OXFORD |
| description | <p><strong>Objective:</strong> To understand community seroprevalence of SARS-CoV-2 in children and adolescents. This is vital to understanding the susceptibility of this cohort to COVID-19 and to inform public health policy for disease control such as immunisation.</p>
<p><strong>Design:</strong> We conducted a community-based cross-sectional seroprevalence study in participants aged 0–18 years old recruiting from seven regions in England between October 2019 and June 2021 and collecting extensive demographic and symptom data. Serum samples were tested for antibodies against SARS-CoV-2 spike and nucleocapsid proteins using Roche assays processed at UK Health Security Agency laboratories. Prevalence estimates were calculated for six time periods and were standardised by age group, ethnicity and National Health Service region.</p>
<p><strong>Results:</strong> Post-first wave (June–August 2020), the (anti-spike IgG) adjusted seroprevalence was 5.2%, varying from 0.9% (participants 10–14 years old) to 9.5% (participants 5–9 years old). By April–June 2021, this had increased to 19.9%, varying from 13.9% (participants 0–4 years old) to 32.7% (participants 15–18 years old). Minority ethnic groups had higher risk of SARS-CoV-2 seropositivity than white participants (OR 1.4, 95% CI 1.0 to 2.0), after adjusting for sex, age, region, time period, deprivation and urban/rural geography. In children <10 years, there were no symptoms or symptom clusters that reliably predicted seropositivity. Overall, 48% of seropositive participants with complete questionnaire data recalled no symptoms between February 2020 and their study visit.</p>
<p><strong>Conclusions:</strong> Approximately one-third of participants aged 15–18 years old had evidence of antibodies against SARS-CoV-2 prior to the introduction of widespread vaccination. These data demonstrate that ethnic background is independently associated with risk of SARS-CoV-2 infection in children.</p>
<p><strong>Trial registration number:</strong> NCT04061382.</p> |
| first_indexed | 2024-09-25T04:08:41Z |
| format | Journal article |
| id | oxford-uuid:40ca4953-f93c-4e89-a625-e24f6ccda063 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:08:41Z |
| publishDate | 2022 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:40ca4953-f93c-4e89-a625-e24f6ccda0632024-06-06T14:22:19ZCommunity seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:40ca4953-f93c-4e89-a625-e24f6ccda063EnglishSymplectic ElementsBMJ Publishing Group2022Ratcliffe, HTiley, KSAndrews, NAmirthalingam, GVichos, IMorey, EDouglas, NLMarinou, SPlested, EAley, PGaliza, EPFaust, SNHughes, SMurray, CSRoderick, MShackley, FOddie, SJLees, TTurner, DPJRaman, MOwens, STurner, PCockerill, HLopez Bernal, JLinley, EBorrow, RBrown, KRamsay, MEVoysey, MSnape, MD<p><strong>Objective:</strong> To understand community seroprevalence of SARS-CoV-2 in children and adolescents. This is vital to understanding the susceptibility of this cohort to COVID-19 and to inform public health policy for disease control such as immunisation.</p> <p><strong>Design:</strong> We conducted a community-based cross-sectional seroprevalence study in participants aged 0–18 years old recruiting from seven regions in England between October 2019 and June 2021 and collecting extensive demographic and symptom data. Serum samples were tested for antibodies against SARS-CoV-2 spike and nucleocapsid proteins using Roche assays processed at UK Health Security Agency laboratories. Prevalence estimates were calculated for six time periods and were standardised by age group, ethnicity and National Health Service region.</p> <p><strong>Results:</strong> Post-first wave (June–August 2020), the (anti-spike IgG) adjusted seroprevalence was 5.2%, varying from 0.9% (participants 10–14 years old) to 9.5% (participants 5–9 years old). By April–June 2021, this had increased to 19.9%, varying from 13.9% (participants 0–4 years old) to 32.7% (participants 15–18 years old). Minority ethnic groups had higher risk of SARS-CoV-2 seropositivity than white participants (OR 1.4, 95% CI 1.0 to 2.0), after adjusting for sex, age, region, time period, deprivation and urban/rural geography. In children <10 years, there were no symptoms or symptom clusters that reliably predicted seropositivity. Overall, 48% of seropositive participants with complete questionnaire data recalled no symptoms between February 2020 and their study visit.</p> <p><strong>Conclusions:</strong> Approximately one-third of participants aged 15–18 years old had evidence of antibodies against SARS-CoV-2 prior to the introduction of widespread vaccination. These data demonstrate that ethnic background is independently associated with risk of SARS-CoV-2 infection in children.</p> <p><strong>Trial registration number:</strong> NCT04061382.</p> |
| spellingShingle | Ratcliffe, H Tiley, KS Andrews, N Amirthalingam, G Vichos, I Morey, E Douglas, NL Marinou, S Plested, E Aley, P Galiza, EP Faust, SN Hughes, S Murray, CS Roderick, M Shackley, F Oddie, SJ Lees, T Turner, DPJ Raman, M Owens, S Turner, P Cockerill, H Lopez Bernal, J Linley, E Borrow, R Brown, K Ramsay, ME Voysey, M Snape, MD Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021 |
| title | Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021 |
| title_full | Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021 |
| title_fullStr | Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021 |
| title_full_unstemmed | Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021 |
| title_short | Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021 |
| title_sort | community seroprevalence of sars cov 2 in children and adolescents in england 2019 2021 |
| work_keys_str_mv | AT ratcliffeh communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT tileyks communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT andrewsn communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT amirthalingamg communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT vichosi communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT moreye communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT douglasnl communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT marinous communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT plestede communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT aleyp communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT galizaep communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT faustsn communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT hughess communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT murraycs communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT roderickm communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT shackleyf communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT oddiesj communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT leest communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT turnerdpj communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT ramanm communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT owenss communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT turnerp communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT cockerillh communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT lopezbernalj communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT linleye communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT borrowr communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT brownk communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT ramsayme communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT voyseym communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 AT snapemd communityseroprevalenceofsarscov2inchildrenandadolescentsinengland20192021 |